Cargando…

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma

BACKGROUND: Aberrant epigenetic modifications play a key role in lung tumorigenesis. In our study, we aimed to explore the clinical implications of baseline circulating tumor DNA (ctDNA) somatic and methylation profiles in patients with lung squamous cell carcinoma (LUSC). METHODS: A total of 26 pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yutao, Feng, Yu, Hou, Ting, Lizaso, Analyn, Xu, Feng, Xing, Puyuan, Wang, Hongyu, Kang, Qiaolin, Zhang, Lu, Shi, Yuankai, Hu, Xingsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815356/ https://www.ncbi.nlm.nih.gov/pubmed/33489798 http://dx.doi.org/10.21037/tlcr-20-1070

Ejemplares similares

The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer
por: Feng, Yu, et al.
Publicado: (2022)

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report
por: Liu, Yutao, et al.
Publicado: (2018)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment
por: Ma, Shenglin, et al.
Publicado: (2021)

Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method
por: Tang, Yuan, et al.
Publicado: (2020)

Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy
por: Wu, Shibo, et al.
Publicado: (2020)

Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report
por: Rao, Chuangzhou, et al.
Publicado: (2019)

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report
por: Zhou, Yuling, et al.
Publicado: (2020)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
por: Li, Hang, et al.
Publicado: (2021)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
por: Wang, Mingzhao, et al.
Publicado: (2023)

Prognostic CpG Methylation Biomarkers Identified by Methylation Array in Esophageal Squamous Cell Carcinoma Patients
por: Kuo, I-Ying, et al.
Publicado: (2014)

Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report
por: Liu, Lian-Fang, et al.
Publicado: (2022)

Prognostic biomarker GSTK1 in head and neck squamous cell carcinoma and its correlation with immune infiltration and DNA methylation
por: Feng, Yao, et al.
Publicado: (2023)

Circulating miR-21 as a prognostic and predictive biomarker in oral squamous cell carcinoma
por: Mahmood, Nosheen, et al.
Publicado: (2019)

Circulating uPA as a potential prognostic biomarker for resectable esophageal squamous cell carcinoma
por: He, Xiao, et al.
Publicado: (2019)

Monitoring methylation-driven genes as prognostic biomarkers in patients with lung squamous cell cancer
por: Han, Pengkai, et al.
Publicado: (2020)

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma
por: Han, Xiaohong, et al.
Publicado: (2019)

The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report
por: Liu, Bin, et al.
Publicado: (2021)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review
por: Xie, Tong, et al.
Publicado: (2021)

Identification of Immune-Cell-Related Prognostic Biomarkers of Esophageal Squamous Cell Carcinoma Based on Tumor Microenvironment
por: Cui, Yiyao, et al.
Publicado: (2021)

DNA methylation-mediated Klotho silencing is an independent prognostic biomarker of head and neck squamous carcinoma
por: Zhu, Yun, et al.
Publicado: (2019)

Suitability of Surgical Tumor Tissues, Biopsy, or Cytology Samples for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Carcinoma Based on Chinese Population()()
por: Han, Xiaohong, et al.
Publicado: (2014)

Circulating circERBB2 as a potential prognostic biomarker for gastric cancer: An investigative study
por: Nanishi, Kenji, et al.
Publicado: (2020)

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
por: Feng, Yu, et al.
Publicado: (2022)

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
por: Lou, Ning, et al.
Publicado: (2023)

Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain‐only relapse versus synchronous extracranial relapse
por: Xu, Fei, et al.
Publicado: (2023)

Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

SHISA3 Promoter Methylation Is a Potential Diagnostic and Prognostic Biomarker for Laryngeal Squamous Cell Carcinoma
por: Shen, Zhisen, et al.
Publicado: (2017)

The clinical implications of circulating microRNAs as potential biomarkers in screening oral squamous cell carcinoma
por: Gao, Huan, et al.
Publicado: (2022)

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis
por: Ma, Di, et al.
Publicado: (2017)

Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer
por: Chen, Kezhong, et al.
Publicado: (2023)

A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy
por: Liu, Yutao, et al.
Publicado: (2020)

An integrated methylation and gene expression microarray analysis reveals significant prognostic biomarkers in oral squamous cell carcinoma
por: Zhao, Chenguang, et al.
Publicado: (2018)

Immune Infiltration Represents Potential Diagnostic and Prognostic Biomarkers for Esophageal Squamous Cell Carcinoma
por: Li, Mengxiang, et al.
Publicado: (2022)

DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical Analysis
por: Huang, Liling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_caleqp3rgn1f7h1lo1is57mbno